ACN Newswire

Sat Jul 10

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

Written by ACN Newswire

ADELAIDE, AUS, Jul 9, 2021 - (ACN Newswire) - The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial.

Tetherex Pharmaceuticals, Inc....

ACN Newswire

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

The gender gap in Australia’s hate speech laws

Bitcoin ruling still doesn’t answer which country has the right to tax

Five ethical questions for how we choose to use the Moon

Australia's major summer arts festivals: reckoning with the past or retreating into it?

Politics podcast: Chris Bowen on the budget and Labor's policies

Why we should remember Boorong, Bennelong's third wife, who is buried beside him

How many people make a good city? It's not the size that matters, but how you use it

Australia's links with China must change, but decoupling is not an option

If the government listened to business leaders, they would encourage humanities education, not pull funds from it

Panic attacks aren't necessarily a reason to panic: they are your body's way of responding to stress

Smart Ways to Store Furniture in Melbourne